ArticleClinical and experimental dental research2026
Effect of C5a Receptor Antagonist on the Osteogenic Differentiation of Dental Pulp Stem Cells.
Article in Clinical and experimental dental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveComplement component 5a (C5a) binding to its receptor (C5aR) can mediate pro-inflammatory immune responses, which impairs osteogenic differentiation of dental pulp stem cells (DPSCs). The present study aimed to evaluate the regulatory effect of C5aR antagonist (W54011) on the osteogenic differentiation of DPSCs in an in vitro inflammatory microenvironment and its reparative effect on in vivo LPS-induced inflammatory mandibular defects, to provide novel strategies for bone regeneration under inflammatory conditions. MATERIALS AND
methodsIn vitro, a DPSCs inflammatory model was established with 1.0 μg/mL LPS for 48 h, and cells were divided into four groups (LPS + W54011 + OIM, OIM, W54011 only, blank) with W54011 at 1.0 μg/mL. Each assay included 3 biological and 3 technical replicates, and osteogenic differentiation was assessed via Alkaline Phosphatase (ALP) staining, alizarin red S (ARS) staining, RT-qPCR, and western blotting for OCN, Osterix, and RUNX2. In vivo, an LPS-induced inflammatory mandibular defect model was constructed in Sprague-Dawley (SD) rats; after 2 weeks of inflammation, defects were implanted with W54011-loaded Bio-Oss bone powder, and healing was evaluated by micro-CT, H-E staining, and immunohistochemistry for IL-6, OCN, and RUNX2.
resultsIn vitro, all 4 groups showed positive ALP and mineralized nodule staining. Molecular biology methods found differential OCN, Osterix and RUNX2 expression at day 7, 14 and 21, with the LPS + W54011 + OIM group having higher osteogenesis markers at certain times (p < 0.05, one-way ANOVA with Bonferroni post-hoc test). In vivo, Micro-CT and H&E staining revealed that the defect site implanted with W54011-loaded Bio-Oss (treatment group) exhibited higher bone density and denser new bone formation compared to the control groups. However, due to the small sample size, these results were considered preliminary qualitative observations without statistical analysis.
conclusion1. LPS (1 μg/ml) stimulation for 48 h can be used to establish a DPSCs inflammation model. 2. W54011 can promote the osteogenic differentiation of DPSCs in an inflammatory environment in vitro. 3. Preliminary in vivo data suggest that W54011-loaded Bio-Oss may facilitate the healing of inflammatory mandibular defects, warranting further investigation with larger samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.